Cellectar (CLRB) awards director Andrew Gu 25,000 options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation. On July 7, 2026, he was awarded options covering 25,000 shares of common stock with an exercise price of $2.70 per share and an expiration date of July 7, 2036. According to the footnote, the option vests in full on July 7, 2027, provided he continues to serve the company through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gu Andrew
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 25,000 options
Exercise price: $2.70 per share
Underlying shares: 25,000 shares
+3 more
6 metrics
Options granted
25,000 options
Grant to director Andrew Gu on July 7, 2026
Exercise price
$2.70 per share
Stock option exercise price for granted options
Underlying shares
25,000 shares
Common stock underlying the stock options
Expiration date
July 7, 2036
Option term end date for the grant
Post-grant derivative holdings
25,000 options
Total derivative securities following transaction
Vesting date
July 7, 2027
Option vests in full, subject to continued service
Key Terms
Stock option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more
5 terms
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "2.7000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-07-07T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common stock""
FAQ
What did Cellectar Biosciences (CLRB) director Andrew Gu report on this Form 4?
Andrew Gu reported receiving a grant of stock options for 25,000 shares of Cellectar Biosciences common stock. The options are compensation-related, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.
How many Cellectar Biosciences (CLRB) options did Andrew Gu receive and at what price?
Andrew Gu received stock options for 25,000 shares of Cellectar Biosciences common stock. The options have an exercise price of $2.70 per share, meaning he can buy shares at that price once the options are vested and exercisable.
When do Andrew Gu’s Cellectar Biosciences (CLRB) stock options vest and expire?
The option grant to Andrew Gu vests in full on July 7, 2027, if he continues serving the company through that date. The options carry an expiration date of July 7, 2036, after which any unexercised options will lapse.
Is Andrew Gu’s Form 4 for Cellectar Biosciences (CLRB) a stock purchase or compensation grant?
Andrew Gu’s Form 4 reflects a compensation-related grant of stock options, not an open-market stock purchase. The transaction is coded as a grant or award, giving him rights to acquire shares later at a set exercise price of $2.70.
How many Cellectar Biosciences (CLRB) derivative securities does Andrew Gu hold after this grant?
After this reported transaction, Andrew Gu holds 25,000 stock options as derivative securities. These options relate to 25,000 underlying shares of Cellectar Biosciences common stock, all tied to the single grant disclosed in this Form 4 filing.